The Myth of the Flawless Pipeline: Why Great R&D Leadership Means Being Proud of the No-Go
Ask most people outside biotech what a good drug discovery program looks like, and they will describe a straight line:. A target gets validated, a molecule gets designed, it clears in vitro assaysworks in the lab, it works in animal modelss,and marches into the clinic it works in people. Zero detours. That is not how […]
The Hardest Gate in R&D: When the Biology Says No
The Moment The Data Stops Cooperating At some point in almost every drug discovery program, you reach a moment where the data in front of you refuses to match the narrative you pitched. Maybe a lead candidate that looked pristine in primary cell assays falls apart once you test it in a more complex system. […]